| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
191,170,000 |
| Market
Cap: |
11.81(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$22.35 - $66.62 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile BridegeBio Pharma identifies and improves medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Co.'s pipeline are: Acoramidis/AG10/BBP-265, a small molecule transthyretin (TTR) stabilizer for the treatment of TTR amyloidosis; Infigratinib/BBP-831, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer for the treatment of congenital adrenal hyperplasia; and Encaleret, a small molecule antagonist of the calcium sensing receptor for the treatment of Autosomal Dominant Hypocalcemia Type 1.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
569,746 |
10,708,068 |
20,896,321 |
26,923,262 |
| Total Sell Value |
$32,444,744 |
$419,299,759 |
$764,106,591 |
$921,329,291 |
| Total People Sold |
4 |
9 |
11 |
12 |
| Total Sell Transactions |
11 |
26 |
44 |
59 |
| End Date |
2025-08-10 |
2025-05-09 |
2024-11-08 |
2023-11-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Daniels Ronald J |
Director |
– • – |
2025-11-06 |
4 |
S |
$63.72 |
$3,888,999 |
D/D |
(61,031) |
16,991 |
|
- |
|
| Daniels Ronald J |
Director |
– • – |
2025-11-06 |
4 |
OE |
$34.65 |
$2,114,724 |
D/D |
61,031 |
78,022 |
|
- |
|
| Mccormick Frank |
Director |
– • – |
2025-10-29 |
4 |
AS |
$65.48 |
$13,206,528 |
I/I |
(198,359) |
679,979 |
|
-7% |
|
| Mccormick Frank |
Director |
– • – |
2025-10-27 |
4 |
AS |
$65.00 |
$106,665 |
I/I |
(1,641) |
878,338 |
|
-3% |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-10-09 |
4 |
AS |
$54.80 |
$2,192,092 |
I/I |
(40,000) |
835,686 |
|
13% |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-10-08 |
4 |
AS |
$54.39 |
$2,191,350 |
I/I |
(40,000) |
855,686 |
|
12% |
|
| Mccormick Frank |
Director |
– • – |
2025-09-05 |
4 |
S |
$53.16 |
$3,933,544 |
D/D |
(74,000) |
83,275 |
|
-18% |
|
| Mccormick Frank |
Director |
– • – |
2025-09-05 |
4 |
OE |
$11.92 |
$882,080 |
D/D |
74,000 |
157,275 |
|
- |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-09-05 |
4 |
AS |
$51.95 |
$2,122,047 |
I/I |
(40,000) |
875,686 |
|
16% |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-09-04 |
4 |
AS |
$51.15 |
$2,053,788 |
I/I |
(40,000) |
895,686 |
|
19% |
|
| Trimarchi Thomas |
President and CFO |
• – – |
2025-08-21 |
4 |
S |
$49.48 |
$2,090,081 |
D/D |
(42,237) |
421,081 |
|
-25% |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-08-20 |
4 |
AS |
$48.81 |
$1,276,927 |
D/D |
(26,156) |
223,090 |
|
26% |
|
| Trimarchi Thomas |
President and CFO |
• – – |
2025-08-18 |
4 |
AS |
$50.14 |
$871,722 |
D/D |
(17,353) |
463,318 |
|
26% |
|
| Apuli Maricel |
Chief Accounting Officer |
• – – |
2025-08-16 |
4 |
D |
$51.32 |
$245,361 |
D/D |
(4,781) |
137,078 |
|
- |
|
| Trimarchi Thomas |
President and CFO |
• – – |
2025-08-16 |
4 |
D |
$51.32 |
$1,093,988 |
D/D |
(21,317) |
480,671 |
|
- |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-08-16 |
4 |
D |
$51.32 |
$1,686,119 |
D/D |
(32,855) |
249,246 |
|
- |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-08-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
64,697 |
282,101 |
|
- |
|
| Homcy Charles J |
|
– • – |
2025-08-11 |
4 |
AS |
$48.00 |
$2,400,000 |
D/D |
(50,000) |
916,674 |
|
28% |
|
| Homcy Charles J |
|
– • – |
2025-08-08 |
4 |
AS |
$45.87 |
$11,512,443 |
D/D |
(250,000) |
966,674 |
|
33% |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-08-08 |
4 |
AS |
$45.88 |
$1,848,828 |
I/I |
(40,000) |
915,686 |
|
33% |
|
| Apuli Maricel |
Chief Accounting Officer |
• – – |
2025-08-07 |
4 |
S |
$45.44 |
$45,440 |
D/D |
(1,000) |
141,859 |
|
-37% |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-08-07 |
4 |
AS |
$45.09 |
$1,818,121 |
I/I |
(40,000) |
935,686 |
|
34% |
|
| Ellis Andrea |
|
– • – |
2025-08-05 |
4 |
AS |
$49.00 |
$841,183 |
D/D |
(17,167) |
18,589 |
|
26% |
|
| Ellis Andrea |
|
– • – |
2025-08-05 |
4 |
OE |
$16.75 |
$287,547 |
D/D |
17,167 |
35,756 |
|
- |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-07-02 |
4 |
AS |
$42.73 |
$1,709,050 |
I/I |
(40,000) |
955,686 |
|
44% |
|
404 Records found
|
|
Page 1 of 17 |
|
|
0.93 (1.48%) 
